According to some netizens, "the local drug calls out some drugs from the medical insurance directory is because the medical insurance funds are not enough", the relevant person in charge of the Medical Service Management Department of the National Medical Security Bureau denied it, and saidThe national medical insurance fund is balanced, with a slight balance, the scale of revenue and expenditure is compatible with the level of economic development, and the fund guarantee capabilities are stable and sustainable.
According to a press release issued by the China National Medical Insurance Bureau's website, the person in charge said that in 2021, the national basic medical insurance fund (including maternity insurance) revenue of 2.88 trillion yuan (RMB, the same below, about 59 trillion yuanXinyuan), expenditure 2.4 trillion yuan.Generally speaking, the national medical insurance fund's balance of payments is balanced, slightly balanced, the scale of revenue and expenditure is compatible with the economic development level, and the fund guarantee capabilities are stable and sustainable.In fact, it was the strong guarantee of the medical insurance fund that since the establishment of the State Medical Insurance Administration in 2018, many new drugs have gradually transferred to the medical insurance directory, achieving a significant expansion of medical insurance drug security and significantly improved levels.
The person in charge said that while steadily expanding the national medical insurance and drug directory, in response to the problems of imbalanced development of the medical insurance industry, the State Medical Insurance Bureau actively and steadily promoted the basic unified scope of medical insurance for medical insurance.Fund tolerance, clinical and mass medication habits, drug renewal cycles and other factors have studied and formulated a three -year "digestion" plan for local supplements, that is, from 2020, according to 40%and 40%of the second year of the first year, 40%of the first year, 40%of the second year, 40%The proportion of 20%in the third year gradually disrupted the drugs that were adjusted in accordance with the regulations in the original provincial drug directory, and the scope of national medical insurance drugs would be basically unified by the end of 2022.
The person in charge explained that at the beginning of the establishment of the basic medical insurance system, the state allowed provincesThe actual situation such as medication habits can be added to themselves, but it cannot exceed 15%of the number of "category B drugs" of the national directory. This is a strategy for the right to the medical insurance environment at that time.In recent years, China's medical security industry has developed rapidly. The national medical insurance and drug catalogs have been dynamically adjusted every year. In the past 4 years, more than 500 new drugs and good drugs have been included in the directory, and the drug prices have been greatly reduced after negotiation.This is not the past, local supplements can be better replaced by medicines in the national catalog, and it is not of great significance to continue to retain local supplements.Balance.
Therefore, the basis of medical insurance drugs is basically unified, which is an important measure to solve the problem of inadequate problems in the field of medical security in my country.As of June 30 this year, 15 provinces in the country and the Xinjiang Production and Construction Corps have completed the "digestion" task of supplementary drugs in advance, including the "digestion" of the remaining 16 provinces, including Beijing, this year.At the end of the year.By the end of 2022, all provinces across the country will complete the "digestion" of local supplementary drugs to achieve basically unified scope of medical insurance for medical insurance.Generally speaking, the advancement of this work is smooth and orderly, and clinical and mass medication is basically not affected.
